All Posts Tagged With: "ELN"
(PML) Stronger Label Warnings for Biogen Idec’s Tysabri
The US Food and Drug Administration (FDA) recently issued a notice on its website regarding the risk of developing progressive multifocal leukoencephalopathy (PML) with increased use of Tysabri. Tysabri, which is marketed by Biogen Idec (
1Mar2010 | vitalstocks | 0 comments | Continued(BIIB) Biogen Idec Beats Expectations and Guides Higher
Biogen Idec Inc. (BIIB) reported fourth quarter earnings per share of $1.18, beating the Zacks Consensus Estimate of $1.05. The company reported earnings of 91 cents in the year-ago period.
Performance...
(BIIB) Biogen’s Tysabri European Medicines Agency Review Finished
Last week, the European Medicines Agency (EMEA) finalized a review of Biogen Idec’s (BIIB) Tysabri (natalizumab) and the risk of progressive multifocal leukoencephalopathy (PML) associated with the prolonged...
(ACOR) Acorda Therapeutics’ Multiple Sclerosis Drug Gets FDA Clearance
Recently, Acorda Therapeutics Inc. (ACOR) announced that the U.S. Food and Drug Administration (FDA) has cleared its oral drug Ampyra (dalfampridine) which aims to improve walking speed in patients suffering...
(BIIB) Biogen’s Tysabri is a Blockbuster!
Biogen Idec Inc. (BIIB) recently announced that its multiple sclerosis (MS) drug Tysabri achieved blockbuster status in 2009. Sales of the drug, which is approved for relapsing forms of MS in the US and for...
(BIIB) Biogen Idec Announces New PML Cases In Patients Taking Their Multiple Sclerosis Drug Tysabri
Biogen Idec Inc. (BIIB) recently announced that 4 more cases of progressive multifocal leukeoencephalopathy (PML), a potentially deadly brain infection, were observed in November in patients taking its multiple...
(JNJ) Johnson & Johnson Aquires a Privately-Held Medical Devices Company
Johnson & Johnson’s (JNJ) surgical care company Ethicon decided to acquire a privately-held medical devices company, Acclarent, for approximately $785 million. The transaction, expected to close...
(GSK) GlaxoSmithKline Earns FDA Approval for Arzerra, a Chronic Lymphocytic Leukemia Drug
GlaxoSmithKline (GSK) and Denmark-based Genmab received some good news with the US Food and Drug Administration’s (FDA) approval for Arzerra (ofatumumab), a monoclonal antibody for patients with chronic...
(BIIB) Biogen Reports Higher Earnings
Today morning, Biogen Idec (BIIB) reported third quarter earnings per share of $1.12, beating the Zacks Consensus Estimate of $1.02. The company reported earnings of 98 cents in the year-ago period. Revenues increased 3% to...
(ABT) Two Pharmas Are Better Than One – Here Are the Ones to Buy in This Merger-Mad Industry
Tony Daltorio, Investment U Research
Pharmaceutical companies have launched themselves into the fall season with a vengeance, gobbling up acquisitions like dots on a Pac-Man board.
The most notable recent buyout was a deal that sees Abbott...
(JNJ) Johnson & Johnson Beast Estimates and Raises Guidance
Johnson & Johnson’s (JNJ) third quarter earnings of $1.20 surpassed the Zacks Consensus Estimate by 7 cents and by 3 cents from the year-ago period.
However, the company reported revenues of $15.1 billion, a decline of 5.3% compared to the third...
(ELN) SEC Subpoena for Elan Regarding Tysabri Use Disclosure
Elan Corporation (ELN) recently received a subpoena from the US Securities and Exchange Commission (SEC) regarding the company’s disclosure of two brain disorder cases (in July 2008), often fatal, tied to the use of its drug Tysabri for the treatment of...
(ELN) Elan Redesigns Johnson & Johnson Deal to Satisfy Biogen
We believe the dispute between Elan Corp. (ELN) and its US partner Biogen Idec (BIIB) over multiple-sclerosis drug Tysabri has been resolved at last. The row started when Elan signed a deal with Johnson & Johnson (JNJ)...
(BIIB) Court Rules in Favor of Biogen Idec
Biogen Idec (BIIB) received good news yesterday in the form of a favorable court ruling in its dispute with partner Elan Corp. PLC (ELN) regarding their 10-year collaboration for multiple sclerosis drug Tysabri.
As a reminder, Elan...
(PFE) Pharmaceuticals & Biotech – Zacks Analyst Interviews
The pharmaceutical industry is entering a period of substantial change in 2009. Most of the names in the industry are facing significant patent challenges in the years to come. U.S.-based firms are facing foreign exchange headwinds, as well. Revenue growth is non-existent,...
(PFE) Pharmaceuticals & Biotech – Industry Outlook
The pharmaceutical industry is entering a period of substantial change in 2009. Most of the names in the industry are facing significant patent challenges in the years to come. U.S.-based firms are facing foreign exchange headwinds, as well. Revenue growth is non-existent,...